Comments

Cidara Therapeutics

CDTXNASDAQ
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$13.24
1.2910.79%
At Close: -
$12.20
-1.04-7.85%
After Hours: Jul 24, 7:38 PM EDT
15 minutes delayed
Cidara Therapeutics (CDTX) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$40.00
Lowest Price Target1
$6.00
Consensus Price Target1
$19.75

Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Click Here

Cidara Therapeutics (NASDAQ:CDTX) Stock, Analyst Ratings, Price Targets, Forecasts

Cidara Therapeutics Inc has a consensus price target of $19.75 based on the ratings of 6 analysts. The high is $40 issued by WBB Securities on April 25, 2024. The low is $6 issued by HC Wainwright & Co. on April 8, 2024. The 3 most-recent analyst ratings were released by Needham, WBB Securities, and Needham on May 16, 2024, April 25, 2024, and April 25, 2024, respectively. With an average price target of $30 between Needham, WBB Securities, and Needham, there's an implied 145.90% upside for Cidara Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
3
Apr
0
0
0
0
May
1
Jun
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.3
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Needham
WBB Securities
HC Wainwright & Co.
Aegis Capital

1calculated from analyst ratings

Analyst Ratings for Cidara Therapeutics

Buy NowGet Alert
06/20/2024Buy Now—Cantor Fitzgerald
Louise Chen
—Reiterates → OverweightGet Alert
05/16/2024Buy Now104.92%Needham
Joseph Stringer
 → $25ReiteratesBuy → BuyGet Alert
04/25/2024Buy Now227.87%WBB Securities
Stephen Brozak
 → $40MaintainsStrong BuyGet Alert
04/25/2024Buy Now104.92%Needham
Joseph Stringer
$3 → $25MaintainsBuyGet Alert
04/25/2024Buy Now—Cantor Fitzgerald
Louise Chen
—Reiterates → OverweightGet Alert
04/23/2024Buy Now—Cantor Fitzgerald
Louise Chen
—Reiterates → OverweightGet Alert
04/08/2024Buy Now-50.82%HC Wainwright & Co.
Ed Arce
$120 → $120MaintainsBuyGet Alert
12/07/2023Buy Now-50.82%HC Wainwright & Co.
Ed Arce
 → $120ReiteratesBuy → BuyGet Alert
11/06/2023Buy Now-50.82%HC Wainwright & Co.
Ed Arce
 → $120ReiteratesBuy → BuyGet Alert
09/22/2023Buy Now-75.41%Needham
Joseph Stringer
 → $60ReiteratesBuy → BuyGet Alert
09/22/2023Buy Now-50.82%HC Wainwright & Co.
Ed Arce
 → $120ReiteratesBuy → BuyGet Alert
09/08/2023Buy Now-75.41%Needham
Joseph Stringer
 → $60ReiteratesBuy → BuyGet Alert
09/07/2023Buy Now-50.82%HC Wainwright & Co.
Ed Arce
 → $120ReiteratesBuy → BuyGet Alert
08/07/2023Buy Now-50.82%HC Wainwright & Co.
Ed Arce
 → $120Reiterates → BuyGet Alert
08/04/2023Buy Now-75.41%Needham
Joseph Stringer
 → $60ReiteratesBuy → BuyGet Alert
08/01/2023Buy Now-50.82%HC Wainwright & Co.
Ed Arce
 → $120Reiterates → BuyGet Alert
08/01/2023Buy Now-59.02%Cantor Fitzgerald
Louise Chen
 → $100ReiteratesOverweight → OverweightGet Alert
06/26/2023Buy Now-50.82%HC Wainwright & Co.
Ed Arce
 → $120ReiteratesBuy → BuyGet Alert
05/15/2023Buy Now-50.82%HC Wainwright & Co.
Ed Arce
 → $120ReiteratesBuy → BuyGet Alert
05/12/2023Buy Now-75.41%Needham
Joseph Stringer
 → $60ReiteratesBuy → BuyGet Alert
04/18/2023Buy Now-75.41%Needham
Joseph Stringer
 → $60Reiterates → BuyGet Alert
03/24/2023Buy Now-50.82%HC Wainwright & Co.
Ed Arce
 → $120Reiterates → BuyGet Alert
03/23/2023Buy Now-50.82%HC Wainwright & Co.
Ed Arce
$130 → $120MaintainsBuyGet Alert
03/08/2023Buy Now-59.02%Cantor Fitzgerald
Louise Chen
 → $100Reiterates → OverweightGet Alert
03/01/2023Buy Now-46.72%HC Wainwright & Co.
Ed Arce
 → $130Reiterates → BuyGet Alert
01/25/2023Buy Now-46.72%HC Wainwright & Co.
Ed Arce
$120 → $130MaintainsBuyGet Alert
05/12/2022Buy Now-50.82%HC Wainwright & Co.
Ed Arce
$150 → $120MaintainsBuyGet Alert
09/22/2021Buy Now-34.43%Aegis Capital
Nathan Weinstein
$180 → $160MaintainsBuyGet Alert
09/22/2021Buy Now—WBB Securities
Steve Brozak
—UpgradeBuy → Strong BuyGet Alert

FAQ

Q

What is the target price for Cidara Therapeutics (CDTX) stock?

A

The latest price target for Cidara Therapeutics (NASDAQ:CDTX) was reported by Cantor Fitzgerald on June 20, 2024. The analyst firm set a price target for $0.00 expecting CDTX to fall to within 12 months (a possible -100.00% downside). 17 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Cidara Therapeutics (CDTX)?

A

The latest analyst rating for Cidara Therapeutics (NASDAQ:CDTX) was provided by Cantor Fitzgerald, and Cidara Therapeutics reiterated their overweight rating.

Q

When was the last upgrade for Cidara Therapeutics (CDTX)?

A

The last upgrade for Cidara Therapeutics Inc happened on September 22, 2021 when WBB Securities raised their price target to N/A. WBB Securities previously had a buy for Cidara Therapeutics Inc.

Q

When was the last downgrade for Cidara Therapeutics (CDTX)?

A

There is no last downgrade for Cidara Therapeutics.

Q

When is the next analyst rating going to be posted or updated for Cidara Therapeutics (CDTX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cidara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cidara Therapeutics was filed on June 20, 2024 so you should expect the next rating to be made available sometime around June 20, 2025.

Q

Is the Analyst Rating Cidara Therapeutics (CDTX) correct?

A

While ratings are subjective and will change, the latest Cidara Therapeutics (CDTX) rating was a reiterated with a price target of $0.00 to $0.00. The current price Cidara Therapeutics (CDTX) is trading at is $12.20, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch